Abstract:Gefitinib has shown efficacy in patients with non-small-cell lung cancer (NSCLC) and brain metastases. However there have been only a few case reports about its concentration in cerebrospinal fluid (CSF). We measured concentrations of gefitinib in both CSF and plasma in 22 patients. The results showed that the CSF gefitinib concentration was low, and there was a positive correlation between the concentration of gefitinib in CSF and gefitinib in plasma. This study suggested that patients with NSCLC and brain metastases may benefit from increasing the gefitinib dose for new intracranial lesions.Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have high response and disease control rates in patients with central nervous system (CNS) metastases. However there have been only a few case reports on the penetration of gefitinib into the cerebrospinal fluid (CSF). The aim of this study was to investigate the CSF concentration of gefitinib in Chinese patients with lung adenocarcinomas. Methods: From March 2007 to December 2010, 22 patients were sequentially enrolled in this study at Peking Union Medical College Hospital (PUMCH). CSF and plasma samples were collected at the same time from each patient after at least 7 doses of gefitinib. The concentrations of gefitinib in the CSF and plasma were measured by high performance liquid chromatography coupled with tandem mass spectrometry. The clinical factors that may affect gefitinib penetration were analyzed. Results: The mean plasma and CSF concentrations of gefitinib were 491.8 +/- 184.2 ng/mL and 6.2 +/- 4.6 ng/mL, respectively, and the mean ratio of CSF-plasma concentration was 1.3% +/- 0.7%. There was a good correlation between CSF and plasma gefitinib concentrations (R = 0.556, P = .006). The presence of CNS metastases was associated with increased gefitinib CSF penetration (1.46% vs. 0.95%; P = .042). Conclusions: The concentration of gefitinib in CSF was low, and it was significantly related to the plasma gefitinib concentration. Because of the inadequate CNS drug exposure, patients in whom the extracranial lesions were well controlled may benefit from increasing gefitinib dose for the new intracranial lesions. Clinical Lung Cancer, Vol. 14, No. 2, 188-93 (c) 2013 Elsevier Inc. All rights reserved.

Cranberry Ingestion Modulated Drug Transporters and Metabolizing Enzymes: Gefitinib Used as a Probe Substrate in Rats

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Cranberry Phytochemical Extract Inhibits SGC-7901 Cell Growth and Human Tumor Xenografts in Balb/c Nu/nu Mice.

Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters

Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

Bidirectional Influences of Cranberry on the Pharmacokinetics and Pharmacodynamics of Warfarin with Mechanism Elucidation

Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model

Evaluation of the in vitro/in vivo potential of five berries (bilberry, blueberry, cranberry, elderberry, and raspberry ketones) commonly used as herbal supplements to inhibit uridine diphospho-glucuronosyltransferase

Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: A Novel Guanylate Cyclase Stimulator

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer

A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans

Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers

Cerebrospinal Fluid Concentrations of Gefitinib in Patients with Lung Adenocarcinoma

Simultaneous Determination of Gefitinib and Its Major Metabolites in Mouse Plasma by HPLC-MS/MS and Its Application to a Pharmacokinetics Study.

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

Mechanisms of gefitinib-induced QT prolongation

Functional Characterization of Wild-Type and 24 Cyp2d6 Allelic Variants on Gefitinib Metabolism in Vitro

Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects

Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer

A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids